LifeStance Health Group, Inc. (NASDAQ:LFST) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of LifeStance Health Group, Inc. (NASDAQ:LFST) have been assigned an average rating of “Moderate Buy” from the nine research firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $8.8333.

LFST has been the subject of several recent research reports. Wall Street Zen raised LifeStance Health Group from a “hold” rating to a “buy” rating in a report on Friday, January 23rd. Barclays assumed coverage on shares of LifeStance Health Group in a research note on Tuesday, December 9th. They issued an “overweight” rating and a $8.00 target price for the company. Zacks Research downgraded shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 5th. BTIG Research increased their price target on shares of LifeStance Health Group from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, December 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of LifeStance Health Group in a research report on Monday, December 29th.

Insider Activity

In other LifeStance Health Group news, insider Lisa K. Miller sold 57,240 shares of the firm’s stock in a transaction on Friday, November 21st. The stock was sold at an average price of $6.43, for a total value of $368,053.20. Following the completion of the sale, the insider owned 261,292 shares of the company’s stock, valued at approximately $1,680,107.56. This trade represents a 17.97% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Ann Varanakis sold 50,000 shares of the company’s stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $6.90, for a total transaction of $345,000.00. Following the transaction, the insider directly owned 315,610 shares in the company, valued at approximately $2,177,709. This trade represents a 13.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 327,326 shares of company stock valued at $2,259,317 in the last three months. 6.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Bayesian Capital Management LP purchased a new stake in shares of LifeStance Health Group during the 2nd quarter worth approximately $52,000. Blair William & Co. IL acquired a new position in LifeStance Health Group during the second quarter worth $70,000. Public Employees Retirement System of Ohio purchased a new stake in LifeStance Health Group during the second quarter worth $70,000. Vanguard Personalized Indexing Management LLC purchased a new stake in LifeStance Health Group during the third quarter worth $72,000. Finally, CIBC Bancorp USA Inc. acquired a new stake in LifeStance Health Group in the third quarter valued at $78,000. 85.50% of the stock is owned by hedge funds and other institutional investors.

LifeStance Health Group Stock Down 2.9%

Shares of NASDAQ:LFST opened at $7.10 on Wednesday. LifeStance Health Group has a 1-year low of $3.74 and a 1-year high of $8.30. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.58 and a quick ratio of 1.58. The stock has a market cap of $2.76 billion, a P/E ratio of -236.67 and a beta of 1.12. The firm has a fifty day moving average price of $6.92 and a 200 day moving average price of $5.77.

LifeStance Health Group (NASDAQ:LFST) last announced its earnings results on Wednesday, November 5th. The company reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $0.03. The business had revenue of $363.81 million during the quarter, compared to the consensus estimate of $355.06 million. LifeStance Health Group had a negative net margin of 0.67% and a negative return on equity of 0.62%. The business’s quarterly revenue was up 16.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.02) earnings per share. Sell-side analysts predict that LifeStance Health Group will post -0.18 EPS for the current year.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.